Crystalys Therapeutics Inc. has launched with a $205m Series A financing to support its mission of addressing the significant unmet medical needs of people living with gout.
The financing round will support the advancement of global phase 3 clinical studies evaluating the company’s lead asset, dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential best-in-class safety and efficacy for the treatment of gout. Dotinurad has already demonstrated robust efficacy and a well-defined safety profile across multiple clinical studies, supporting its approval in Japan, China, Philippines and Thailand.
“Crystalys was built to bring forward a new therapeutic option for the millions of people struggling with gout,” said James Mackay, president and chief executive officer of Crystalys Therapeutics.
“Our lead asset, with its proven efficacy and well-defined safety profile, has already demonstrated its ability to provide meaningful relief for people living with gout. Thanks to the support of our investors, our experienced team is now well-positioned to accelerate dotinurad’s development in the US and Europe as a much needed second-line therapy for patients who do not respond adequately to first-line treatments.”
“Since its inception, Crystalys has been guided by a singular vision: uniting a world-class gout drug development team with Japan’s excellence in pharmaceutical innovation to deliver transformative therapies for patients with gout,” said BT Slingsby, co-founder and chairman of the board of Crystalys Therapeutics.
“The clinical effectiveness of dotinurad for treating hyperuricemia associated with gout has already been well validated across 22 trials involving 1,300 subjects, and since its approval in Japan in 2020, more than 1.2m patients have been treated with dotinurad, consistently achieving target serum uric acid levels linked to meaningful clinical benefits,” said Nihar Bhakta, chief medical officer of Crystalys Therapeutics.
“Our upcoming phase 3 trials are designed to highlight the superior efficacy of dotinurad in reducing serum uric acid levels, gout flares and tophus area.”
The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
